Dianabol (Methandrostenolone) 20mg/tab 100 tabs – Medical Pharma Steroids USA

Description

Dianabol (Methandrostenolone) 20mg/tab 100 tabs – Medical Pharma Steroids USA C20H28O2 = 300.4. CAS — 72-63-9. ATC — A14AA03; D11AE01. ATC Vet — QA14AA03; QD11AE01. NOTE. The following terms have been used as ‘street names’ or slang names for various forms of methandienone: Iron Brew. Pharmacopoeias. In Pol Dynabol contains: 20mg ⦁ 20 mg / tab Methandrostenolone. Pharmacologic category Androgen. Dosing: Adult 20 mg every 24 hours. Deep intramuscular injection. Dosing: Geriatric Refer to adult dosing Dosing: Pediatric Has not been studied in pediatric population. Dosing: Renal impairment No dosage adjustment provided in manufacturer’s labeling; use with caution due to propensity to cause edema. Dosing: Hepatic impairment No dosage adjustment provided in manufacturer’s labeling; use with caution. Use Methandienone has anabolic and some androgenic properties. It has little progestogenic activity. Methandienone has been given orally as an anabolic drug. Storage/Stability Store in at room temperature in a dark and dry place. Contraindications Hypersensitivity to methandienone or any component of the formulation. Warnings/Precautions ⦁ Gynecomastia: May cause Gynecomastia. ⦁ Hepatic effects: Prolonged use and/or high doses may cause peliosis hepatis or liver cell tumors, which may not be apparent until liver failure or intra-abdominal hemorrhage develops. Discontinue in case of cholestatic hepatitis with jaundice or abnormal liver function tests. ⦁ Venous thromboembolism: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported with testosterone products. Evaluate patients with symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those with acute shortness of breath for PE. Discontinue therapy if a venous thromboembolism is suspected. Disease related concerns: ⦁ Breast cancer: Use with caution in patients with breast cancer; may cause hypercalcemia by stimulating osteolysis. ⦁ Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention. ⦁ Hepatic impairment: Use with caution in patients with hepatic impairment. Pregnancy risk factor X Category X: Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. Pregnancy considerations Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported. Lactation Excretion in breast milk unknown/not recommended Breast feeding considerations It is not known if methandienone is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended. Adverse reactions As with other 17α-alkylated compounds, methandienone is associated with hepatotoxicity and hepatic function should be monitored during therapy. It should probably be avoided in patients with hepatic impairment, and certainly if this is severe. Frequency unknown. Cardiovascular: Edema Central nervous system: Depression, excitation, insomnia Dermatologic: Acne (females and prepubertal males) Also reported in females: Hirsutism, male-pattern baldness. Endocrine & metabolic: Electrolyte imbalances, glucose intolerance, gonadotropin secretion inhibited, gynecomastia, HDL decreased, LDL increased, libido changes. Also reported in females: Clitoral enlargement, menstrual irregularities. Genitourinary: Prepubertal males: Increased or persistent erections, penile enlargement. Postpubertal males: Bladder irritation, epididymitis, impotence, oligospermia, priapism (chronic), testicular atrophy, testicular function inhibited. Hematologic: Prothrombin time increased, suppression of clotting factors. Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, bilirubin increased, cholestatic jaundice, hepatic necrosis (rare), hepatocellular neoplasms, peliosis hepatis (with long-term therapy). Neuromuscular & skeletal: CPK increased, premature closure of epiphyses (in children). Renal: Creatinine excretion increased. Metabolism/Transport effects None known. Drug interactions Corticosteroids, Warfarin and Antidiabetic agents. Test interactions May suppress factors II, V, VII, and X; may increase PT; may decrease thyroxine-binding globulin and radioactive iodine uptake Monitoring parameters Liver function tests, cholesterol profile, hemoglobin/hematocrit; INR/PT in patients on anticoagulant therapy. Children: Radiographs of left wrist and hand every 6 months (to assess bone maturation). Adult females: Signs of virilization (deepening voice, hirsutism, acne, clitoromegaly); urine and serum calcium in women with breast cancer.. Dosage Forms 25mg/tab daily Anatomic Therapeutic Chemical (ATC) Classification ⦁ A14AA03; D11AE01. Mechanism of action Methandrostenolone is a 17alpha-alkylated anabolic-androgenic steroid and a synthetic derivative of testosterone with a similar mechanism of action to other anabolic steroids. Pharmacodynamics/Kinetics Methandrostenolone is a modified form of testosterone. The resulting steroid also has a much weaker relative binding affinity for the androgen receptor than testosterone, but at the same time displays a much longer half-life and lower affinity for serum-binding proteins in comparison. These features allow methandrostenolone to be a very potent anabolic steroid in spite of a weaker affinity for receptor binding. Metabolism: hepatic Half-life: 3-5 hours. Buy Methandrostenolone steroid online USA.